We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.8B
AUM Growth
-$577M
Cap. Flow
-$347M
Cap. Flow %
-3.21%
Top 10 Hldgs %
77.46%
Holding
139
New
12
Increased
27
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$517M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$232M
3
DBVT
DBV Technologies
DBVT
+$142M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$66.6M
5
NGNE icon
Neurogene
NGNE
+$63.9M

Top Sells

Rank Stock Value
1
XOMA
Xoma
XOMA
+$57M
2
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$29.2M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.1M
4
OMER icon
Omeros
OMER
+$9.78M
5
DYAX
DYAX CORPORATION
DYAX
+$8.72M

Sector Composition

Rank Sector Weight
1 Healthcare 74.03%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.2B
$2.15B 19.85%
19,474,969
+4,609,410
+31% +$517M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$1.39B 12.84%
36,029,746
+5,159,484
+17% +$232M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.02B 9.45%
6,542,599
– –
ABBV icon
4
AbbVie
ABBV
$469B
$782M 7.23%
14,373,538
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.46B
$677M 6.26%
20,481,442
– –
ANAC
6
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$487M 4.5%
4,135,412
+509,914
+14% +$66.6M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$11.9B
$429M 3.97%
4,076,353
-18,894
-0.5% -$2.52M
GHDX
8
DELISTED
Genomic Health, Inc.
GHDX
$289M 2.67%
13,658,328
+730
+0% +$18.8K
DBVT
9
DBV Technologies
DBVT
$799M
$194M 1.8%
546,202
+360,000
+193% +$142M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.44B
$161M 1.49%
14,110,179
+2,532,880
+22% +$33.8M
DYAX
11
DELISTED
DYAX CORPORATION
DYAX
$144M 1.33%
7,561,480
-365,150
-5% -$8.72M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$102M 0.94%
2,955,074
+150,000
+5% +$4.53M
NGNE icon
13
Neurogene
NGNE
$648M
$94.9M 0.88%
337,367
+277,499
+464% +$63.9M
HRTX icon
14
Heron Therapeutics
HRTX
$92.5M
$71M 0.66%
2,907,784
+100,000
+4% +$3.33M
CERS icon
15
Cerus
CERS
$573M
$61.5M 0.57%
13,553,275
– –
BLCM
16
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$60.9M 0.56%
419,059
– –
ONCE
17
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$52.7M 0.49%
1,262,382
– –
NVTA
18
DELISTED
Invitae Corporation
NVTA
$47.3M 0.44%
6,554,967
– –
ARAV
19
DELISTED
Aravive, Inc. Common Stock
ARAV
$37.4M 0.35%
540,297
-32,467
-6% -$3.05M
IMGN
20
DELISTED
Immunogen Inc
IMGN
$34.1M 0.31%
3,548,040
+1,227,616
+53% +$17.9M
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.2B
$29.9M 0.28%
750,739
+208,503
+38% +$10.1M
INSM icon
22
Insmed
INSM
$22.5B
$29.4M 0.27%
1,583,490
– –
ACOR
23
DELISTED
Acorda Therapeutics
ACOR
$29.1M 0.27%
9,141
+2,983
+48% +$11.6M
MDVN
24
DELISTED
MEDIVATION, INC.
MDVN
$28M 0.26%
+659,752
New +$32.7M
HALO icon
25
Halozyme
HALO
$9.84B
$25.9M 0.24%
1,931,057
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Baker Bros. Advisors held 139 positions worth $10.8B, down 5.1% from $11.4B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $347M in Q3 2015, closing 6 positions and reducing 8 holdings. Its most notable exit was Xoma, an estimated $57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 72% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in MEDIVATION, INC. worth $28M.

  • Baker Bros. Advisors's largest Q3 2015 buy was MEDIVATION, INC.: 659,752 shares worth $28M.
  • Baker Bros. Advisors added most to Incyte in Q3 2015, an estimated $517M increase.
  • Baker Bros. Advisors's biggest Q3 2015 reduction was Alder Biopharmaceuticals, cutting an estimated $16.1M.
  • Baker Bros. Advisors fully exited Xoma in Q3 2015, selling an estimated $57M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $10.8B portfolio in Q3 2015.
  • Baker Bros. Advisors opened 12 new positions and closed 6 in Q3 2015.
  • Baker Bros. Advisors's portfolio value fell 5.1% quarter-over-quarter to $10.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.